Advanced glycation end products among patients maintained on antipsychotics

Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Karsten Suhre, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Yahya Hani, Reem El Sherbiny, Hassen Al Amin

Research output: Contribution to journalArticle

Abstract

The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P<0.05). The levels of AGEs were higher among the group of patients maintained on antipsychotics in comparison to controls; however, the difference did not reach statistical significance. This is the first study to examine AGEs in patients maintained on antipsychotics. Our findings showed that such patients do not differ significantly from controls comparing AGEs levels. Future investigations might need to consider recruiting a larger sample size using a prospective design.

Original languageEnglish
Pages (from-to)256-261
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume32
Issue number5
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Advanced Glycosylation End Products
Antipsychotic Agents
Qatar
Sample Size
Psychiatry
Primary Health Care
Population

Keywords

  • AGE Reader
  • Antipsychotics
  • Arabs
  • Mental health

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Advanced glycation end products among patients maintained on antipsychotics. / Hammoudeh, Samer; Ghuloum, Suhaila; Mahfoud, Ziyad; Yehya, Arij; Mook-Kanamori, Dennis; Mook-Kanamori, Marjonneke; Suhre, Karsten; Abdulhakam, Abdulmoneim; Al-Mujalli, Azza; Hani, Yahya; El Sherbiny, Reem; Al Amin, Hassen.

In: International Clinical Psychopharmacology, Vol. 32, No. 5, 01.01.2017, p. 256-261.

Research output: Contribution to journalArticle

Hammoudeh, S, Ghuloum, S, Mahfoud, Z, Yehya, A, Mook-Kanamori, D, Mook-Kanamori, M, Suhre, K, Abdulhakam, A, Al-Mujalli, A, Hani, Y, El Sherbiny, R & Al Amin, H 2017, 'Advanced glycation end products among patients maintained on antipsychotics', International Clinical Psychopharmacology, vol. 32, no. 5, pp. 256-261. https://doi.org/10.1097/YIC.0000000000000179
Hammoudeh S, Ghuloum S, Mahfoud Z, Yehya A, Mook-Kanamori D, Mook-Kanamori M et al. Advanced glycation end products among patients maintained on antipsychotics. International Clinical Psychopharmacology. 2017 Jan 1;32(5):256-261. https://doi.org/10.1097/YIC.0000000000000179
Hammoudeh, Samer ; Ghuloum, Suhaila ; Mahfoud, Ziyad ; Yehya, Arij ; Mook-Kanamori, Dennis ; Mook-Kanamori, Marjonneke ; Suhre, Karsten ; Abdulhakam, Abdulmoneim ; Al-Mujalli, Azza ; Hani, Yahya ; El Sherbiny, Reem ; Al Amin, Hassen. / Advanced glycation end products among patients maintained on antipsychotics. In: International Clinical Psychopharmacology. 2017 ; Vol. 32, No. 5. pp. 256-261.
@article{91ce3a188c4a47819488b6c1c3f5d01e,
title = "Advanced glycation end products among patients maintained on antipsychotics",
abstract = "The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P<0.05). The levels of AGEs were higher among the group of patients maintained on antipsychotics in comparison to controls; however, the difference did not reach statistical significance. This is the first study to examine AGEs in patients maintained on antipsychotics. Our findings showed that such patients do not differ significantly from controls comparing AGEs levels. Future investigations might need to consider recruiting a larger sample size using a prospective design.",
keywords = "AGE Reader, Antipsychotics, Arabs, Mental health",
author = "Samer Hammoudeh and Suhaila Ghuloum and Ziyad Mahfoud and Arij Yehya and Dennis Mook-Kanamori and Marjonneke Mook-Kanamori and Karsten Suhre and Abdulmoneim Abdulhakam and Azza Al-Mujalli and Yahya Hani and {El Sherbiny}, Reem and {Al Amin}, Hassen",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/YIC.0000000000000179",
language = "English",
volume = "32",
pages = "256--261",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Advanced glycation end products among patients maintained on antipsychotics

AU - Hammoudeh, Samer

AU - Ghuloum, Suhaila

AU - Mahfoud, Ziyad

AU - Yehya, Arij

AU - Mook-Kanamori, Dennis

AU - Mook-Kanamori, Marjonneke

AU - Suhre, Karsten

AU - Abdulhakam, Abdulmoneim

AU - Al-Mujalli, Azza

AU - Hani, Yahya

AU - El Sherbiny, Reem

AU - Al Amin, Hassen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P<0.05). The levels of AGEs were higher among the group of patients maintained on antipsychotics in comparison to controls; however, the difference did not reach statistical significance. This is the first study to examine AGEs in patients maintained on antipsychotics. Our findings showed that such patients do not differ significantly from controls comparing AGEs levels. Future investigations might need to consider recruiting a larger sample size using a prospective design.

AB - The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded. Among the group maintained on antipsychotics, women, smokers, and Arabs had significantly higher AGEs levels compared with men, nonsmokers, and non-Arabs, respectively (P<0.05). The levels of AGEs were higher among the group of patients maintained on antipsychotics in comparison to controls; however, the difference did not reach statistical significance. This is the first study to examine AGEs in patients maintained on antipsychotics. Our findings showed that such patients do not differ significantly from controls comparing AGEs levels. Future investigations might need to consider recruiting a larger sample size using a prospective design.

KW - AGE Reader

KW - Antipsychotics

KW - Arabs

KW - Mental health

UR - http://www.scopus.com/inward/record.url?scp=85026844684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026844684&partnerID=8YFLogxK

U2 - 10.1097/YIC.0000000000000179

DO - 10.1097/YIC.0000000000000179

M3 - Article

VL - 32

SP - 256

EP - 261

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -